APPLICATION
NDA017875
TYPE
NDA
ORIGINAL APPROVAL
1976-10-01
LATEST ACTION
2023-01-04
ROUTE
ORAL-21
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LOESTRIN 21 1.5/30 · ReferenceDiscontinued
ETHINYL ESTRADIOL 0.03MG, NORETHINDRONE ACETATE 1.5MG · TABLET · ORAL-21
Approval history
2014-09-26Manufacturing (CMC) · Supplement 34 · standardAP
1999-11-24Labeling · Supplement 30 · standardAP
1999-03-31Labeling · Supplement 31 · standardAP
1999-01-08Labeling · Supplement 29 · standardAP
1998-01-16Labeling · Supplement 28 · standardAP
1997-11-20Manufacturing (CMC) · Supplement 27 · standardAP
1997-07-28Manufacturing (CMC) · Supplement 26 · standardAP
1997-07-28Manufacturing (CMC) · Supplement 25 · standardAP
1996-03-08Labeling · Supplement 18AP
1996-03-08Labeling · Supplement 20 · standardAP
1995-07-07Manufacturing (CMC) · Supplement 24 · standardAP
1994-06-27Manufacturing (CMC) · Supplement 22 · standardAP
1994-06-02Manufacturing (CMC) · Supplement 23 · standardAP
1994-03-07Manufacturing (CMC) · Supplement 21 · standardAP
1993-07-09Manufacturing (CMC) · Supplement 19 · standardAP
1991-04-22Labeling · Supplement 17AP
1989-05-17Manufacturing (CMC) · Supplement 16 · standardAP
1988-09-13Labeling · Supplement 14AP
1988-03-16Manufacturing (CMC) · Supplement 15 · standardAP
1986-06-04Labeling · Supplement 13AP
1985-09-17Manufacturing (CMC) · Supplement 11 · standardAP
1984-10-22Labeling · Supplement 12AP
1982-11-18Manufacturing (CMC) · Supplement 10 · standardAP
1981-11-09Manufacturing (CMC) · Supplement 8 · standardAP
1981-04-08Labeling · Supplement 7AP
1978-06-14Manufacturing (CMC) · Supplement 4 · standardAP
1977-11-10Labeling · Supplement 5AP
1977-02-08Manufacturing (CMC) · Supplement 1 · standardAP
1977-02-08Manufacturing (CMC) · Supplement 2 · standardAP
1976-10-01Type 3 - New Dosage Form · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.